WO2021002476A1 - 標的核酸断片の検出方法及びキット - Google Patents

標的核酸断片の検出方法及びキット Download PDF

Info

Publication number
WO2021002476A1
WO2021002476A1 PCT/JP2020/026371 JP2020026371W WO2021002476A1 WO 2021002476 A1 WO2021002476 A1 WO 2021002476A1 JP 2020026371 W JP2020026371 W JP 2020026371W WO 2021002476 A1 WO2021002476 A1 WO 2021002476A1
Authority
WO
WIPO (PCT)
Prior art keywords
nucleic acid
acid fragment
target nucleic
protein
crispr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/JP2020/026371
Other languages
English (en)
French (fr)
Japanese (ja)
Inventor
力也 渡邉
理 濡木
弘志 西増
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
RIKEN
Original Assignee
RIKEN
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by RIKEN filed Critical RIKEN
Priority to JP2021529209A priority Critical patent/JP7579577B2/ja
Priority to US17/620,868 priority patent/US12522859B2/en
Priority to EP20834193.3A priority patent/EP3995833A4/en
Priority to CA3143923A priority patent/CA3143923A1/en
Priority to CN202080047412.4A priority patent/CN114072520A/zh
Publication of WO2021002476A1 publication Critical patent/WO2021002476A1/ja
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6816—Hybridisation assays characterised by the detection means
    • C12Q1/6818—Hybridisation assays characterised by the detection means involving interaction of two or more labels, e.g. resonant energy transfer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N11/00—Carrier-bound or immobilised enzymes; Carrier-bound or immobilised microbial cells; Preparation thereof
    • C12N11/02—Enzymes or microbial cells immobilised on or in an organic carrier
    • C12N11/08—Enzymes or microbial cells immobilised on or in an organic carrier the carrier being a synthetic polymer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6806—Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6834—Enzymatic or biochemical coupling of nucleic acids to a solid phase
    • C12Q1/6837—Enzymatic or biochemical coupling of nucleic acids to a solid phase using probe arrays or probe chips

Definitions

  • the present invention relates to a method and a kit for detecting a target nucleic acid fragment.
  • the present application claims priority based on Japanese Patent Application No. 2019-125564 filed in Japan on July 4, 2019, the contents of which are incorporated herein by reference.
  • cfDNA cell-free DNA
  • ctDNA blood tumor DNA
  • exosomes secrete membrane vesicles
  • biological samples such as saliva, blood, urine, amniotic fluid, and malignant ascites, and in the supernatant of cultured cells.
  • Exosomes contain various proteins, lipids, microRNAs, DNAs, etc. derived from the cells that secrete them.
  • Non-Patent Documents 1 to 3 report a method for detecting a target nucleic acid fragment with high sensitivity by utilizing such activities of Cas12 and Cas13.
  • an object of the present invention is to provide a technique capable of detecting a target nucleic acid fragment with high sensitivity without amplifying it.
  • a method for detecting a target nucleic acid fragment in a sample which is a step of contacting the sample with a gRNA complementary to the target nucleic acid fragment, a CRISPR / Cas family protein, and a substrate nucleic acid fragment.
  • the CRISPR / Cas family protein expresses nuclease activity after forming a tripartite complex with the gRNA and the target nucleic acid fragment, and the substrate nucleic acid fragment is labeled with a fluorescent substance and a dimming substance.
  • the fluorescent substance When the fluorescent substance is cleaved by the nuclease activity of the tripartite complex and separates from the extinguishing substance, it fluoresces by irradiation with excitation light, and the contact is performed in a reaction space having a volume of 10 aL to 100 pL.
  • the target nucleic acid fragment when the target nucleic acid fragment is present in the sample, the tripartite complex is formed, the substrate nucleic acid fragment is cleaved, the fluorescent substance is separated from the extinguishing substance, and the fluorescent substance is described.
  • a method comprising a step of irradiating with excitation light and detecting the fluorescence, wherein the detection of the fluorescence indicates the presence of the target nucleic acid fragment in the sample.
  • the CRISPR / Cas family includes a substrate having wells having a volume of 10 aL to 100 pL formed on the surface, a gRNA complementary to the target nucleic acid fragment, a CRISPR / Cas family protein, and a substrate nucleic acid fragment.
  • the protein expresses nuclease activity after forming a tripartite complex with the gRNA and the target nucleic acid fragment, and the substrate nucleic acid fragment is labeled with a fluorescent substance and a photochromic substance, and the tripartite complex is formed.
  • a kit for detecting a target nucleic acid fragment which emits fluorescence by irradiation with excitation light when the fluorescent substance is cleaved by the nuclease activity of the above and separates from the extinguishing substance.
  • the CRISPR / Cas family protein is a Cas12 protein or a Cas13 protein.
  • the CRISPR / Cas family protein is immobilized on the inner surface of the well.
  • the present invention it is possible to provide a technique capable of detecting a target nucleic acid fragment with high sensitivity without amplifying it.
  • FIG. 1 A and (b) are schematic diagrams illustrating a method for detecting a target nucleic acid fragment.
  • A is a top view showing an example of a fluid device.
  • B is a cross-sectional view taken along the line bb'of (a).
  • A) to (c) are schematic cross-sectional views illustrating an example of a procedure for carrying out the method of the present embodiment.
  • A)-(d) are schematic diagrams illustrating a method of immobilizing a CRISPR / Cas family protein on the inner surface of a well.
  • A) to (f) are schematic cross-sectional views explaining each step of forming a well array.
  • (A) to (c) are typical fluorescence micrographs showing the results of Experimental Example 1.
  • (D) is a graph showing the result of Experimental Example 1.
  • (A) to (c) are typical fluorescence micrographs showing the results of Experimental Example 2.
  • (D) is a graph showing the results of Experimental Example 2.
  • (A) and (b) are graphs showing the results of Experimental Example 3.
  • (A) to (d) are typical fluorescence micrographs showing the results of Experimental Example 4.
  • (A) and (b) are graphs showing the results of Experimental Example 4. It is a graph which shows the result of Experimental Example 4.
  • the present invention is a method for detecting a target nucleic acid fragment in a sample, which comprises contacting the sample with a gRNA complementary to the target nucleic acid fragment, a CRISPR / Cas family protein, and a substrate nucleic acid fragment.
  • a method comprising a step of irradiating a substrate nucleic acid fragment with excitation light and detecting fluorescence, and the detection of fluorescence indicates that the target nucleic acid fragment is present in the sample.
  • the CRISPR / Cas family protein expresses nuclease activity after forming a tripartite complex with gRNA and the target nucleic acid fragment.
  • the substrate nucleic acid fragment is labeled with a fluorescent substance and a quenching substance, and when the fluorescent substance is cleaved by the nuclease activity of the above-mentioned tripartite complex and the fluorescent substance is separated from the quenching substance, it emits fluorescence by irradiation with excitation light. is there.
  • contact of the sample, gRNA, CRISPR / Cas family protein and substrate nucleic acid fragment is performed in a reaction space having a volume of 10 aL to 100 pL.
  • the target nucleic acid fragment is present in the sample, the above-mentioned tripartite complex is formed, the substrate nucleic acid fragment is cleaved, and the fluorescent substance is separated from the quenching substance. Then, when the excitation light is irradiated, fluorescence is detected.
  • FIGS. 1A and 1B are schematic views illustrating the method of the present embodiment.
  • FIGS. 1A and 1B a case where the CRISPR / Cas family protein is a Cas12a protein will be described as an example.
  • the Cas12a protein 110 and the gRNA 120 are brought into contact with each other, they bind to each other to form a two-way complex 130.
  • the gRNA 120 partially has a base sequence complementary to the target nucleic acid fragment 140.
  • the Cas12a protein 110 does not express nuclease activity, so the substrate nucleic acid fragment 150 is not cleaved.
  • the substrate nucleic acid fragment 150 is a single-stranded DNA fragment labeled with a fluorescent substance F and a quencher Q. No fluorescence is generated even when the substrate nucleic acid fragment 150 is irradiated with excitation light.
  • FIG. 1A is a schematic view showing a tripartite complex 100'in which the target site of the target nucleic acid fragment 140 has been cleaved.
  • FIG. 1 (b) the tripartite complex 100'expresses nuclease activity.
  • the substrate nucleic acid fragment 150 existing around the tripartite complex 100' is cleaved.
  • the fluorescent substance F of the substrate nucleic acid fragment 150 is separated from the quenching substance Q.
  • the fluorescent substance F separated from the quenching substance Q fluoresces when irradiated with excitation light.
  • the fluorescent substance F is irradiated with excitation light to detect fluorescence.
  • fluorescence it can be determined that the target nucleic acid fragment 140 was present in the sample.
  • the sample, gRNA120, CRISPR / Cas family protein 110, and substrate nucleic acid fragment 150 may be mixed and contacted in any order.
  • the gRNA 120 and the CRISPR / Cas family protein 110 may be brought into contact with each other to form the two-party complex 130 in advance, and then the sample may be brought into contact with the sample.
  • the target nucleic acid fragment 140 if the target nucleic acid fragment 140 is present in the sample, the target nucleic acid fragment 140 binds to the two-way complex 130 to form the three-way complex 100.
  • the substrate nucleic acid fragment 150 may then be contacted.
  • the target nucleic acid fragment 140 and the substrate nucleic acid fragment 150 may be brought into contact with each other at the same time.
  • gRNA120, CRISPR / Cas family protein 110, and sample may be brought into contact at the same time. Even in this case, if the target nucleic acid fragment 140 is present in the sample, the tripartite complex 100 is finally formed. The substrate nucleic acid fragment 150 may then be contacted.
  • the sample, gRNA 120, CRISPR / Cas family protein 110, and substrate nucleic acid fragment 150 may be brought into contact at the same time. Even in this case, if the target nucleic acid fragment 140 is present in the sample, the tripartite complex 100 is finally formed, and when the target site of the target nucleic acid fragment 140 is cleaved in the tripartite complex 100, It is converted to the tripartite complex 100', expresses nuclease activity, and the substrate nucleic acid fragment 150 is cleaved.
  • sample The sample is not particularly limited and may be appropriately selected depending on the intended purpose.
  • a biological sample such as saliva, blood, urine, amniotic fluid, malignant ascites, pharyngeal swab, nasal swab, or on cultured cells. Qing and others can be mentioned.
  • Target nucleic acid fragment examples include the above-mentioned cfDNA, ctDNA, microRNA, exosome-derived DNA and the like.
  • cfDNA cfDNA
  • ctDNA ctDNA
  • microRNA exosome-derived DNA
  • a mutation of the oncogene contained in the sample can be detected.
  • the CRISPR / Cas family protein is a Cas12 protein
  • a double-stranded DNA fragment can be detected as a target nucleic acid fragment.
  • the CRISPR / Cas family protein is Cas13 protein
  • a single-strand RNA fragment or a single-strand DNA fragment can be detected as a target nucleic acid fragment.
  • the guide RNA is not particularly limited as long as it can be used for the CRISPR / Cas family protein to be used, and the CRISPR RNA (crRNA) and the transactivated CRISPR RNA (tracrRNA). It may be a complex with, a single gRNA (sgRNA) which is a combination of tracrRNA and crRNA, or only crRNA.
  • the crRNA can be, for example, the following base sequence.
  • the base sequence obtained by removing the protospacer adjacent motif (PAM) sequence from the target base sequence is used as the spacer base sequence.
  • PAM protospacer adjacent motif
  • a base sequence in which a scaffold sequence is linked to the 3'end of the spacer base sequence is designed, and the complementary strand thereof is used as the base sequence of crRNA.
  • the base sequence obtained by removing the PAM sequence from the target base sequence is "5'-GCCAAGCGCACCTAATTTCC-3'" (SEQ ID NO: 1)
  • the base sequence of crRNA for Cas12a protein is "5'-AAUUUCUACUAAGUGUAGAUGGAAAUUAGGUGCGCUUGGC-3'”. (SEQ ID NO: 2) can be used.
  • the crRNA can be, for example, the following base sequence.
  • a base sequence in which a scaffold sequence is linked to the 3'end of a base sequence complementary to the target base sequence is designed, and the complementary strand is used as the base sequence of crRNA.
  • the target base sequence is "5'-AUGGAUUACUUGGUAGAACAGCAAUCUA-3'" (SEQ ID NO: 3)
  • the base sequence of crRNA for Cas13a protein is "5'-GAUUUAGACUACCCCAAAAACGAAGGGGACUAAAACUAGAUUGCUGUUCUACCAAGUAAUCCAU-3'" (SEQ ID NO: 4). Can be done.
  • the target base sequence is a partial base sequence of the base sequence of the target nucleic acid fragment. At least one target base sequence is set in one type of target nucleic acid fragment. By setting a plurality of types of target base sequences in one type of target nucleic acid fragment, a ternary complex of a plurality of molecules can be formed on one molecule of the target nucleic acid fragment.
  • the number of molecules of the tripartite complex formed on one molecule of the target nucleic acid fragment can be increased.
  • the present invention is a method for increasing the detection sensitivity in the above-mentioned method for detecting a target nucleic acid fragment, and by using a plurality of types of gRNA, a plurality of molecules are placed on one molecule of the target nucleic acid fragment.
  • a method including a step of forming a tripartite complex of.
  • the CRISPR / Cas family protein can be used as long as it expresses nuclease activity after forming a tripartite complex with gRNA and a target nucleic acid fragment. As mentioned above, more precisely, it forms a tripartite complex and expresses nuclease activity after the CRISPR / Cas family protein cleaves the target nucleic acid fragment.
  • CRISPR / Cas family proteins examples include Cas12 protein and Cas13 protein.
  • the Cas12 protein and Cas13 protein may be Cas12 protein, Cas13 protein, orthologs of these proteins, variants of these proteins, and the like.
  • CRISPR / Cas family proteins that can be used in the method of this embodiment include, for example, Lachnospiraceae bacterium ND2006-derived Cas12a protein (LbCas12a, UniProtKB accession number: A0A182DWE3), Acidaminococcus. Derived Cas12a protein (AsCas12a, UniProtKB accession number: U2UMQ6), Francisella tularensis subsp.
  • Cas12a protein (FnCas12a, UniProtKB accession number: A0Q7Q2) derived from novicida
  • Cas12b protein (AaCas12b, UniProtKB accession number: T0D7A2) derived from Acidoterrestris (AaCas12b, UniProtKB accession number: T0D7A2), Le ), Lachnospiraceae bacterium NK4A179-derived Cas13a protein (LbaCas13a, NCBI accession number: WP_022785443.1), Leptotricia buccalis C-1013-b-derived Cas13a protein (LbaCas13a, NCBI accession number: WP_022785443.1) Cas13b protein (BzoCas13b, NCBI accession number: WP_002664492), Cas13b protein derived from Prevotella intermedia (PinCas13b, NCBI accession number
  • Cas13b protein derived from MA2016 (PsmCas13b, NCBI accession number: WP_036929175), Cas13b protein derived from Riemerala anatipesifer (RanCas13b, NCBI accession number: WP_004919755), PrevotellaCabsession number: WP_004919755, Prevotella Prevotella saccharolytica derived Cas13b protein (PsaCas13b, NCBI accession number: WP_051522484), Cas13b protein derived from Prevotella intermedia (Pin2Cas13b, NCBI accession number: WP_061868553), Cas13b protein derived from Capnocytophaga canimorsus (CcaCas13b, NCBI accession number: WP_013997271) , Porphyromonas gulae-derived Cas13b protein (PguCas13b, NCBI accession number:
  • Cas13b protein derived from P5-125 (PspCas13b, NCBI accession number: WP_044065294), Cas13b protein derived from Porphyromonas gingivalis (PigCas13b, NCBI accession number: WP_0534444417), PrevotellaAncsessionnumber: WP_053444417, Prevotella ), Csm6 protein derived from Enterococcus italicus (EiCsm6, NCBI accession number: WP_007208953.1), Csm6 protein derived from Lactobacillus salivarius (LsCsm6, NCBI accession number: WP_081509), Csm6 protein derived from LsCsm6, NCBI accession number: WP_081509 Accession number: WP_11229148.1) and the like can be mentioned.
  • the CRISPR / Cas family protein may be a variant of the Cas family protein described above.
  • the mutant for example, a mutant having increased nuclease activity after forming a tripartite complex can be used.
  • the substrate nucleic acid fragment is labeled with a fluorescent substance and a quenching substance, and when the fluorescent substance is cleaved by the nuclease activity of the tripartite complex and the fluorescent substance separates from the quenching substance, it emits fluorescence by irradiation with excitation light. ..
  • the substrate nucleic acid fragment may be appropriately selected according to the substrate specificity of the CRISPR / Cas family protein to be used.
  • the Cas12 protein cleaves single-stranded DNA as a substrate. Therefore, when Cas12 protein is used, it is preferable to use single-strand DNA as a substrate nucleic acid fragment.
  • Cas13 protein is cleaved using single-stranded RNA as a substrate. Therefore, when Cas13 protein is used, it is preferable to use single-strand RNA as a substrate nucleic acid fragment.
  • the combination of the fluorescent substance and the quenching substance use a combination that can quench the fluorescence of the fluorescent substance when they are brought close to each other.
  • FAM fluorescent substance
  • HEX HEX
  • TAMRA TAMRA
  • the base sequence of the single-stranded RNA to be cleaved has specificity depending on the type of Cas13 protein. Specifically, for example, it has been reported that the LwaCas13a protein, the CcaCas13b protein, the LbaCas13a protein, and the PsmCas13b protein recognize and cleave the base sequences of AU, UC, AC, and GA in the substrate nucleic acid fragment, respectively.
  • LwaCas13a protein, CcaCas13b protein, LbaCas13a protein, and PsmCas13b protein are used as CRISPR / Cas family proteins, and different gRNAs are bound to each CRISPR / Cas family protein as gRNA to form a substrate.
  • a single-stranded RNA containing the base sequences of AU, UC, AC, and GA as the nucleic acid fragment
  • four types are used in one reaction space.
  • Target nucleic acid fragment can be detected. That is, multicolor detection can be performed.
  • reaction space As a method for accurately detecting a target substance, a technique for performing an enzymatic reaction in a large number of minute reaction spaces is being studied. These methods are called digital measurements. In digital measurement, a sample is divided into a large number of minute reaction spaces to detect signals.
  • the signal from each reaction space is binarized, only the presence or absence of the target substance is determined, and the number of molecules of the target substance is measured. According to the digital measurement, the detection sensitivity and the quantitativeness can be remarkably improved as compared with the conventional Elisa, real-time PCR method and the like.
  • the method of this embodiment is performed by digital measurement. More specifically, the contact of the sample, the CRISPR / Cas family protein, the gRNA, and the substrate nucleic acid fragment is divided into minute reaction spaces.
  • the volume per reaction space is 10 aL to 100 pL, for example, 10 aL to 10 pL, for example, 10 aL to 1 pL, for example, 10 aL to 100 fL, for example, 10 aL to 10 fL. You may.
  • the reaction space is in the above range, it is possible to detect the presence of the target nucleic acid fragment with high sensitivity without amplifying it.
  • Digital measurement can be performed by performing the method of the present embodiment under the condition that 0 or 1 target nucleic acid fragments are introduced per reaction space. That is, the number of reaction spaces in which the signal is detected can be made to correspond to the number of molecules of the target nucleic acid fragment in the sample.
  • the reaction space may be, for example, a droplet.
  • the reaction space may be a well formed on the substrate.
  • FIG. 2A is a top view showing an example of a fluid device including a substrate having a well having a volume of 10 aL to 100 pL formed on the surface of each well.
  • FIG. 2B is a cross-sectional view taken along the line bb'of FIG. 2A.
  • the fluid device 200 has a substrate 210 having a well 211 having a volume of 10aL to 100pL formed on its surface, a spacer 220, and a lid having a liquid inlet 231 formed therein. It has a member 230. There are a plurality of wells 211, forming a well array 212. The space between the substrate 210 and the lid member 230 functions as a flow path for flowing a sample, gRNA, CRISPR / Cas family protein, substrate nucleic acid fragment, and the like.
  • the shape of the well is not particularly limited as long as the volume is within the above range, and the well may be, for example, a cylinder, a polyhedron composed of a plurality of faces (for example, a rectangular parallelepiped, a hexagonal column, an octagonal column, etc.). You may.
  • a plurality of wells 211 having the same shape and the same size form a well array 212.
  • the same shape and the same size may be the same shape and the same capacity as required for digital measurement, and variations in the degree of manufacturing error are acceptable.
  • 3 (a) to 3 (c) are schematic cross-sectional views illustrating an example of a procedure for carrying out the method of the present embodiment using the fluid device 200.
  • the sample, gRNA, and CRISPR / Cas family protein are mixed to form a tripartite complex.
  • the assay solution 310 is prepared by mixing the tripartite complex and the substrate nucleic acid fragment, and immediately introduced from the liquid inlet 231 of the fluid device 200.
  • the space inside the well 211 and between the substrate 210 and the lid member 230 is filled with the assay solution 310.
  • the sealant 320 is introduced from the liquid introduction port 231.
  • an organic solvent containing lipid 321 is used as the sealing agent 320.
  • the lipid 321 natural lipids derived from soybeans, Escherichia coli and the like, artificial lipids such as dioleoylphosphatidylethanolamine (DOPE) and dioleoylphosphatidylglycerol (DOPG) can be used. Hexadecane or chloroform can be used as the organic solvent.
  • DOPE dioleoylphosphatidylethanolamine
  • DOPG dioleoylphosphatidylglycerol
  • Hexadecane or chloroform can be used as the organic solvent.
  • each well 211 becomes an independent reaction space.
  • the well array 212 may be irradiated with excitation light to measure the fluorescence.
  • a lipid membrane can be further laminated on the first lipid membrane 322 to form a lipid bilayer membrane.
  • a membrane-forming aqueous solution 330 for forming the lipid bilayer membrane 324 is introduced from the liquid introduction port 231.
  • a 10 mM pH buffer solution (pH 5 to 9) for example, a 10 mM sodium chloride aqueous solution, or the like can be used.
  • the second lipid membrane 323 is laminated on the first lipid membrane 322 to form the lipid bilayer membrane 324.
  • each well 211 becomes an independent reaction space.
  • the well array 212 may be irradiated with excitation light to measure the fluorescence.
  • the lipid vesicles can be fused to the lipid bilayer membrane 324.
  • the contents of the exosome can be released into the well 211.
  • gRNA, CRISPR / Cas family protein, and substrate nucleic acid fragment are first sealed in well 211, and the opening of well 211 is sealed with a lipid bilayer membrane 324, and then exosomes are used as a sample. It may be brought into contact with the bilayer film 324.
  • the exosome is fused to the lipid bilayer membrane 324, and the contents of the exosome are released into the well 211.
  • a target nucleic acid fragment is present in the contents of the exosome, a tripartite complex is formed inside the well 211, the substrate nucleic acid fragment is cleaved, and fluorescence is detected by irradiation with excitation light.
  • the CRISPR / Cas family protein 110 may be previously immobilized on the inner surface of the well 211 in the method of the present embodiment.
  • the CRISPR / Cas family protein 110 may bind to the gRNA 120 to form a two-way complex 130.
  • a functional group existing on the inner surface of the well 211 and a functional group existing on the surface of the CRISPR / Cas family protein using physical adsorption and a chemical linker are used.
  • a method of covalently combining with and the like can be mentioned.
  • the functional group include a hydroxyl group, an amino group and a thiol group.
  • the CRISPR / Cas family protein may be immobilized on the inner surface of the well 211 by utilizing a click reaction using an azide group and an alkyne group.
  • the invention comprises a well-formed substrate having a volume of 10 aL to 100 pL, a gRNA complementary to the target nucleic acid fragment, a CRISPR / Cas family protein, and a substrate nucleic acid fragment.
  • the CRISPR / Cas family protein expresses nuclease activity after forming a tripartite complex with the gRNA and the target nucleic acid fragment, and the substrate nucleic acid fragment is labeled with a fluorescent substance and a photochromic substance.
  • kits for detecting the target nucleic acid fragment which emits fluorescence by irradiation with excitation light when the fluorescent substance is cleaved by the nuclease activity of the tripartite complex and separates from the extinguishing substance.
  • the above-mentioned method for detecting a target nucleic acid fragment can be preferably carried out.
  • the substrate, the target nucleic acid fragment, the gRNA, the CRISPR / Cas family protein, and the substrate nucleic acid fragment having wells having a volume of 10 aL to 100 pL formed on the surface are the same as those described above.
  • the CRISPR / Cas family protein may be a Cas12 protein or a Cas13 protein.
  • the specific Cas12 protein or Cas13 protein is the same as described above.
  • the CRISPR / Cas family protein 110 may be immobilized on the inner surface of the well 211.
  • the CRISPR / Cas family protein 110 may bind to the gRNA 120 to form a two-way complex 130.
  • the method of fixing the CRISPR / Cas family protein to the inner surface of the well is the same as described above.
  • the gRNA 120 may be fixed to the inner surface of the well 211.
  • an additional sequence that functions as a linker may be added to the gRNA 120.
  • the CRISPR / Cas family protein 110 when the CRISPR / Cas family protein 110 is introduced into the well 211, the CRISPR / Cas family protein 110 binds to the gRNA 120 to form a two-way complex 130, and the well 211 is formed. It is fixed to the inner surface of.
  • wells with fixed gRNA are easier to store than wells with fixed protein.
  • the expression vector of Leptotricia wadei Cas13a was transfected into Escherichia coli BL21 (DE3) strain and expressed.
  • the expression vector was a pET-based vector having a 10 ⁇ His tag, maltose-binding protein (MBP) and a TEV protease cleavage site at the N-terminus.
  • the expressed Cas13a protein was purified using a Ni-NTA resin. Subsequently, after reacting TEV protease at 4 ° C.
  • the target nucleic acid fragment (double-stranded DNA fragment) was prepared by annealing a single-stranded DNA fragment (SEQ ID NO: 5) and a single-stranded DNA fragment complementary thereto, which were chemically synthesized by outsourcing (IDT).
  • the target nucleic acid fragment (single-strand RNA fragment, SEQ ID NO: 6) was chemically synthesized by outsourcing (IDT).
  • gRNA DNA fragment encoding gRNA (crRNA) was prepared by PCR amplification using an overlapping primer containing a T7 promoter sequence, a target sequence of 20 bases, and a scaffold sequence as a template. Subsequently, the obtained DNA fragment was subjected to an in vitro transcription reaction to prepare crRNA.
  • the nucleotide sequence of gRNA (crRNA) for Cas12a protein is shown in SEQ ID NO: 2
  • the nucleotide sequence of gRNA (crRNA) for Cas13a protein is shown in SEQ ID NO: 4.
  • Substrate nucleic acid fragments (single-strand DNA fragments) were chemically synthesized by outsourcing (IDT).
  • the 5'end of the substrate nucleic acid fragment was labeled with FAM, a fluorescent material, and the 3'end was labeled with Iowa Black FQ (IDT), a quencher.
  • the base sequence of the chemically synthesized substrate nucleic acid fragment (single-strand DNA fragment) was "5'-(FAM) TTATT (IABkFQ) -3'" (where "IABkFQ” indicates Iowa Black FQ). ..
  • the substrate nucleic acid fragment (single-strand RNA fragment) was chemically synthesized by outsourcing (IDT).
  • the 5'end of the substrate nucleic acid fragment was labeled with FAM, which is a fluorescent substance, and the 3'end was labeled with Iowa Black FQ (IDT), which is a quencher.
  • the base sequence of the chemically synthesized substrate nucleic acid fragment (single-strand RNA fragment) was "5'-(FAM) UUUUU (IABkFQ) -3'" (where "IABkFQ" indicates Iowa Black FQ). ..
  • FIG. 5A is a schematic cross-sectional views illustrating each step of forming a well array.
  • the glass substrate 210 was immersed in a 10 M potassium hydroxide solution for about 24 hours to form a hydroxyl group on the surface.
  • a fluororesin (CYTOP, manufactured by AGC Inc.) was spin-coated on the surface of the glass substrate 210 to form a film 520.
  • the spin coating condition was 2000 rps (revolution per second) for 30 seconds. Under this condition, the film thickness of the film 520 is about 500 nm.
  • the film 520 was brought into close contact with the surface of the glass substrate 510 by dehydrating and condensing the silanol group of the film 520 (CYTOP) and the hydroxyl group on the glass surface by baking on a hot plate at 180 ° C. for 1 hour.
  • CYTOP silanol group of the film 520
  • a resist (AZ-4903, manufactured by AZ Electrical Materials) was spin-coated on the surface of the film 520 at 4000 rps for 60 seconds to form a resist film 530.
  • the glass substrate 210 was baked on a hot plate at 110 ° C. for 1 hour to evaporate the organic solvent in the resist film 530, whereby the resist film 530 was brought into close contact with the surface of the film 520.
  • the resist film 530 was exposed by irradiating the resist film 530 with ultraviolet rays at 250 W for 7 seconds with an exposure machine (manufactured by SAN-EI) using a mask with a well array pattern. Subsequently, it was immersed in a developing solution (AZ developer, manufactured by AZ Electrical Materials) for 5 minutes for development. As a result, the resist film 530 at the portion forming the well was removed.
  • AZ developer manufactured by AZ Electrical Materials
  • the film 520 is masked with a resist film 530 by using the Reactice ion etching apparatus (Samco, Inc.), O 2 50 sccm, pressure 10 Pa, under the conditions of output 50 W 30 Wells 211 were formed on the film 520 by dry etching for minutes.
  • the Reactice ion etching apparatus Standard, Inc.
  • O 2 50 sccm O 2 50 sccm
  • pressure 10 Pa under the conditions of output 50 W 30
  • Wells 211 were formed on the film 520 by dry etching for minutes.
  • the glass substrate 210 was immersed in acetone, washed with isopropanol, and then washed with pure water to remove the resist film 530 and obtain an array of wells 211.
  • the well array 212 had a shape in which 1,000,000 columnar wells 211 having a diameter of 4 ⁇ m and a depth of 500 nm were arranged in 1 cm 2 .
  • the volume of the well array 212 per well was 6 fL.
  • FIGS. 2A and 2B a glass plate in which the spacer 220 is arranged on the substrate 210 on which the well 211 produced as described above is formed on the surface, and further, the liquid introduction port 231 is formed. 230 was placed and a fluid device was made. As a result, the fluid device 200 is formed in which the space between the well array 212 and the glass plate 230 is a flow path.
  • buffer B having the composition shown in Table 2 below.
  • FIG. 6A is a typical fluorescence micrograph showing the results of an assay solution in which the final concentration of the tripartite complex is 17 pM.
  • FIG. 6B is a representative fluorescence micrograph showing the results of the assay solution having a final concentration of the tripartite complex of 67 pM.
  • FIG. 6 (c) is a representative fluorescence micrograph showing the results of an assay solution in which the final concentration of the tripartite complex is 133 pM.
  • FIG. 6D is a graph showing the result of calculating the ratio of wells in which fluorescence was detected based on a photograph of a well array into which each assay solution was introduced.
  • an assay solution in which the above-mentioned tripartite complex solution and a solution of the substrate nucleic acid fragment were mixed was prepared, and immediately introduced from the liquid inlet of each fluid device. As a result, the assay solution was introduced into each well of the well array.
  • FIG. 7A is a typical fluorescence micrograph showing the results of an assay solution in which the final concentration of the target nucleic acid fragment is 4 pM.
  • FIG. 7B is a representative fluorescence micrograph showing the results of an assay solution in which the final concentration of the target nucleic acid fragment is 40 pM.
  • FIG. 7 (c) is a representative fluorescence micrograph showing the results of an assay solution in which the final concentration of the target nucleic acid fragment is 400 pM.
  • FIG. 7D is a graph showing the result of calculating the ratio of wells in which fluorescence was detected based on a photograph of a well array into which each assay solution was introduced.
  • solutions in which substrate nucleic acid fragments were dissolved so as to have a final concentration of 2, 5, and 10 ⁇ M were prepared in buffer B having the composition shown in Table 2 above.
  • the above-mentioned four fluid devices were prepared. Subsequently, the above-mentioned tripartite complex solution and the solution of the substrate nucleic acid fragment are mixed to prepare an assay solution in which the final concentration of the tripartite complex is 30 pM and the final concentration of the substrate nucleic acid fragment is 2, 5, 10 ⁇ M. Each was prepared and immediately introduced through the liquid inlet of each fluid device. Also, for comparison, an assay solution containing no target nucleic acid fragment was prepared and introduced through the liquid inlet of the fluid device. As a result, each assay solution was introduced into each well of each well array.
  • FIG. 8A is a graph summarizing the time course of fluorescence intensity for wells in which fluorescence of each assay solution was detected.
  • the horizontal axis is time (seconds) and the vertical axis is fluorescence intensity.
  • "w / o tgRNA” indicates the result of the assay solution containing no target nucleic acid fragment
  • "w / tgRNA” indicates the result of the assay solution containing the target nucleic acid fragment
  • “FAM-Q” indicates a substrate nucleic acid fragment.
  • FIG. 8B is a graph showing the relationship between the concentration of the substrate nucleic acid fragment and the rate of increase in fluorescence intensity based on FIG. 8A.
  • the horizontal axis shows the concentration of the substrate nucleic acid fragment ( ⁇ M), and the vertical axis shows the rate of increase in fluorescence intensity ( ⁇ I / s).
  • ⁇ M concentration of the substrate nucleic acid fragment
  • ⁇ I / s rate of increase in fluorescence intensity
  • an assay solution in which the above-mentioned tripartite complex solution and a solution of the substrate nucleic acid fragment were mixed was prepared, and immediately introduced from the liquid inlet of each fluid device. As a result, the assay solution was introduced into each well of the well array.
  • FIG. 9A is a typical fluorescence micrograph showing the results of an assay solution in which the final concentration of the target nucleic acid fragment is 0 pM.
  • FIG. 9B is a representative fluorescence micrograph showing the results of an assay solution in which the final concentration of the target nucleic acid fragment is 0.3 pM.
  • FIG. 9 (c) is a representative fluorescence micrograph showing the results of an assay solution in which the final concentration of the target nucleic acid fragment is 3 pM.
  • FIG. 9D is a typical fluorescence micrograph showing the result of the assay solution in which the final concentration of the target nucleic acid fragment is 30 pM.
  • the scale bar is 50 ⁇ m.
  • FIG. 10A is a typical graph showing the number of wells showing a predetermined fluorescence intensity (relative value) based on a photograph of a well array into which each assay solution was introduced.
  • FIG. 10 (b) shows the same graph as in FIG. 10 (a) for the assay solution in which the final concentrations of the target nucleic acid fragments are 30 pM, 3 pM, 0.3 pM, and 0 pM, respectively, in FIG. 10 (a). It is a graph which enlarged and arranged the area corresponding to the area surrounded by a dotted line.
  • FIG. 11 is a graph showing the relationship between the number of wells in which fluorescence was detected and the final concentration of the target nucleic acid fragment.
  • the vertical axis shows the number of wells in which fluorescence was detected, and the horizontal axis shows the final concentration of the target nucleic acid fragment.
  • solid circles indicate the results of using a fluid device, and dashed circles indicate the results of a similar experiment using a plate reader.
  • the upper left graph in FIG. 11 shows an enlarged view. In experiments with plate readers, 384-well plates were used instead of fluid devices. As a result, it was found that the detection sensitivity when the fluid device was used was 56 fM.
  • the present invention it is possible to provide a technique capable of detecting a target nucleic acid fragment with high sensitivity without amplifying it.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
  • Apparatus Associated With Microorganisms And Enzymes (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
PCT/JP2020/026371 2019-07-04 2020-07-06 標的核酸断片の検出方法及びキット Ceased WO2021002476A1 (ja)

Priority Applications (5)

Application Number Priority Date Filing Date Title
JP2021529209A JP7579577B2 (ja) 2019-07-04 2020-07-06 標的核酸断片の検出方法及びキット
US17/620,868 US12522859B2 (en) 2019-07-04 2020-07-06 Method and kit for detecting target nucleic acid fragment
EP20834193.3A EP3995833A4 (en) 2019-07-04 2020-07-06 METHOD AND KIT FOR DETECTING A TARGET NUCLEIC ACID FRAGMENT
CA3143923A CA3143923A1 (en) 2019-07-04 2020-07-06 Method and kit for detecting target nucleic acid fragment
CN202080047412.4A CN114072520A (zh) 2019-07-04 2020-07-06 检测靶核酸片段的方法及试剂盒

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2019-125564 2019-07-04
JP2019125564 2019-07-04

Publications (1)

Publication Number Publication Date
WO2021002476A1 true WO2021002476A1 (ja) 2021-01-07

Family

ID=74101362

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/JP2020/026371 Ceased WO2021002476A1 (ja) 2019-07-04 2020-07-06 標的核酸断片の検出方法及びキット

Country Status (6)

Country Link
US (1) US12522859B2 (https=)
EP (1) EP3995833A4 (https=)
JP (1) JP7579577B2 (https=)
CN (1) CN114072520A (https=)
CA (1) CA3143923A1 (https=)
WO (1) WO2021002476A1 (https=)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113373264A (zh) * 2021-06-10 2021-09-10 安徽医科大学 一种基于CRISPR/Cas系统的新型冠状病毒双靶标快速检测方法及试剂盒
WO2023195542A1 (ja) * 2022-04-08 2023-10-12 国立研究開発法人理化学研究所 複数種類の標的核酸断片を検出する方法及びキット
WO2024111543A1 (ja) * 2022-11-25 2024-05-30 国立研究開発法人理化学研究所 標的核酸の検出方法及びキット

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114072520A (zh) 2019-07-04 2022-02-18 国立研究开发法人理化学研究所 检测靶核酸片段的方法及试剂盒
US20240094199A1 (en) * 2020-12-28 2024-03-21 Riken Method and kit for detecting target nucleic acid fragment
US20230279375A1 (en) * 2021-12-13 2023-09-07 Labsimply, Inc. Signal boost cascade assay
WO2024072775A1 (en) * 2022-09-26 2024-04-04 The Johns Hopkins University Devices and systems for dna capture

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015115635A1 (ja) * 2014-01-31 2015-08-06 凸版印刷株式会社 生体分子解析キット及び生体分子解析方法
US20170362644A1 (en) * 2016-06-16 2017-12-21 The Regents Of The University Of California Methods and compositions for detecting a target rna
WO2019098301A1 (ja) * 2017-11-17 2019-05-23 凸版印刷株式会社 標的分子の検出方法
WO2019104058A1 (en) * 2017-11-22 2019-05-31 The Regents Of The University Of California Type v crispr/cas effector proteins for cleaving ssdnas and detecting target dnas
JP2019125564A (ja) 2018-01-19 2019-07-25 株式会社豊田自動織機 蓄電モジュール

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3727026B2 (ja) 2003-04-10 2005-12-14 博行 野地 一分子酵素活性検出に用いられるマイクロチャンバと１０００ｆＬ以下の液滴を調製する方法
WO2008105814A2 (en) * 2006-08-22 2008-09-04 Los Alamos National Security, Llc Miniturized lateral flow device for rapid and sensitive detection of proteins or nucleic acids
CN111836903A (zh) * 2017-12-22 2020-10-27 博德研究所 基于crispr效应系统的多重诊断
CA3119971A1 (en) 2018-11-14 2020-05-22 Pardis SABETI Multiplexing highly evolving viral variants with sherlock
CN114072520A (zh) 2019-07-04 2022-02-18 国立研究开发法人理化学研究所 检测靶核酸片段的方法及试剂盒
US20240094199A1 (en) * 2020-12-28 2024-03-21 Riken Method and kit for detecting target nucleic acid fragment

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015115635A1 (ja) * 2014-01-31 2015-08-06 凸版印刷株式会社 生体分子解析キット及び生体分子解析方法
US20170362644A1 (en) * 2016-06-16 2017-12-21 The Regents Of The University Of California Methods and compositions for detecting a target rna
WO2019098301A1 (ja) * 2017-11-17 2019-05-23 凸版印刷株式会社 標的分子の検出方法
WO2019104058A1 (en) * 2017-11-22 2019-05-31 The Regents Of The University Of California Type v crispr/cas effector proteins for cleaving ssdnas and detecting target dnas
JP2019125564A (ja) 2018-01-19 2019-07-25 株式会社豊田自動織機 蓄電モジュール

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
"NCBI", Database accession no. WP 011229148.1
"UniProtKB", Database accession no. AOA182DWE3
CHEN J. S. ET AL.: "CRISPR-Casl2a target binding unleashes indiscriminate single-stranded DNase activity.", SCIENCE, vol. 360, no. 6387, 2018, pages 436 - 439, XP055615609, DOI: 10.1126/science.aar6245
GOOTENBERG J. S. ET AL.: "Multiplexed and portable nucleic acid detection platform with Casl3, Casl2a, and Csm6.", SCIENCE, vol. 360, no. 6387, 2018, pages 439 - 444, XP055538780, DOI: 10.1126/science.aaq0179
GOOTENBERG J. S. ET AL.: "Nucleic acid detection with CRISPR-Casl3a/C2c2.", SCIENCE, vol. 356, no. 6336, 2017, pages 438 - 442, XP055781069, DOI: 10.1126/science.aam9321
See also references of EP3995833A4

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113373264A (zh) * 2021-06-10 2021-09-10 安徽医科大学 一种基于CRISPR/Cas系统的新型冠状病毒双靶标快速检测方法及试剂盒
CN113373264B (zh) * 2021-06-10 2022-04-12 安徽医科大学 一种基于CRISPR/Cas系统的新型冠状病毒双靶标快速检测方法及试剂盒
WO2023195542A1 (ja) * 2022-04-08 2023-10-12 国立研究開発法人理化学研究所 複数種類の標的核酸断片を検出する方法及びキット
WO2024111543A1 (ja) * 2022-11-25 2024-05-30 国立研究開発法人理化学研究所 標的核酸の検出方法及びキット

Also Published As

Publication number Publication date
US20220348993A1 (en) 2022-11-03
CA3143923A1 (en) 2021-01-07
US12522859B2 (en) 2026-01-13
JP7579577B2 (ja) 2024-11-08
EP3995833A1 (en) 2022-05-11
CN114072520A (zh) 2022-02-18
JPWO2021002476A1 (https=) 2021-01-07
EP3995833A4 (en) 2023-08-09

Similar Documents

Publication Publication Date Title
WO2021002476A1 (ja) 標的核酸断片の検出方法及びキット
Lee et al. Polydiacetylene liposome arrays for selective potassium detection
JP2022132281A (ja) バーコード付きオリゴヌクレオチド配列を有する試薬を用いたタンパク質発現の測定
US5723031A (en) Method for the analytical separation of viruses
EP3132049B1 (en) Device and methods of using device for detection of aminoacidopathies
Luo et al. CRISPR/Cas12a‐loaded intelligent DNA hydrogel for universal and ultrasensitive exosome assay
US12226769B2 (en) Sample manipulation and assay with rapid temperature change
Fang et al. CRISPR-cas technology: A key approach for SARS-CoV-2 detection
KR20100001827A (ko) 핵산 추출 방법
Li et al. Ultrahigh-throughput approach for analyzing single-cell genomic damage with an agarose-based microfluidic comet array
EP4269581B1 (en) Method and kit for detecting target nucleic acid fragment
Mojtaba Mousavi et al. Recent progress in prompt molecular detection of exosomes using CRISPR/Cas and microfluidic‐assisted approaches toward smart cancer diagnosis and analysis
Zhu et al. A Novel virus detection strategy enabled by TR512-peptide-based bioorthogonal capture and enrichment of preamplified nucleic acid
Yang et al. From biogenesis to aptasensors: advancements in analysis for tumor-derived extracellular vesicles research
CN116615526B (zh) 靶标物质的检测方法、流体装置及试剂盒
JP7417854B2 (ja) アルカリホスファターゼ組成物並びに脱リン酸化核酸及び標識化核酸の製造方法
JP7402429B2 (ja) アルカリホスファターゼ組成物並びに脱リン酸化核酸及び標識化核酸の製造方法
Wang et al. Rapid, colorimetric and quantitative detection of microcystin-LR using glucose oxidase-modified magnetic beads, CRISPR/Cas12a and recombinase polymerase amplification strategies
Zhang et al. Rapid and Sensitive Detection of miRNA by Single‐Molecule Fluorescence Dequenching Assay with Target Recycled CRISPR/Cas12a Amplification System
Gokul Salivary diagnostics in oral cancer
WO2023195542A1 (ja) 複数種類の標的核酸断片を検出する方法及びキット
WO2024111543A1 (ja) 標的核酸の検出方法及びキット
Waitkus Localized Surface Plasmon Resonance Enhancement from Complex Nanoscale Geometries
JP7402428B2 (ja) 脱リン酸化試薬の品質を評価する方法及び標的核酸を検出する方法
Jacroux Development of microchip isotachophoresis for the detection of novel cardiac troponin I biomarkers

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 20834193

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2021529209

Country of ref document: JP

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 3143923

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2020834193

Country of ref document: EP

Effective date: 20220204

WWG Wipo information: grant in national office

Ref document number: 17620868

Country of ref document: US